Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

Novartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial failed to meet its primary endpoint.

Sarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy treatment.

OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.

The UK MHRA has granted approval for Cybin to initiate the EMBRACE study to assess CYB003 for the adjunctive treatment of MDD.

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.